FindTrial
Sign In

A prospective study on the prevalence and clinical presentation of JAK2 V617F mutation in patients with cerebral infarction.

A prospective study on the prevalence and clinical presentation of JAK2 V617F mutation in patients with cerebral infarction. - A prospective study on the prevalence and clinical presentation of JAK2 V617F mutation in patients with cerebral infarction.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000047136
Enrollment
Unknown
Registered
2022-03-10
Start date
2022-01-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral infarction

Interventions

None listed

Sponsors

Nippon Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients admitted to our department, within 7 days of stroke onset

Exclusion criteria

Exclusion criteria: Patients whose consent cannot be obtained. Patients whose physicians consider them inappropriate due to poor medical conditions.

Design outcomes

Primary

MeasureTime frame
Prevalence of JAK2V617F mutation in patients with cerebral infarction—

Countries

Japan

Contacts

Public ContactToshiyuki Hayashi

Nippon Medical School Neurology

toshi-h-06@nms.ac.jp+81-3-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026